With the FDA approval and launch of the first interchangeable biosimilar in the United States in 2021, retail pharmacists are poised to play an increasing role in the future uptake of biosimilars.
Sonia T. Oskouei, PharmD, BCMAS, DPLA
Advertisement
Articles by Sonia T. Oskouei, PharmD, BCMAS, DPLA
The availability of insulin biosimilars can bring high-quality, lower cost treatment options for pharmacists, physicians, payers, and patients alike.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Addressing Drug Resistance in Lung Cancer
2
From Mutation to Medicine: Targeted Therapies in Lung Cancer
3
TAR-200 Intravesical System Demonstrates Sustained Bladder Exposure in BCG-Unresponsive NMIBC
4
Five-Year NATALEE Data Show Ribociclib Improves Outcomes in High-Risk HR+/HER2– Early Breast Cancer
5
